| Elan CEO to Step Down in 2012 Irish biotech company Elan, facing long-running shareholder dissatisfaction over company management, said Chief Executive Kelly Martin will step down in 2012. online.wsj.com |
Aetna Finds Flaw in Rate Aetna withdrew its request for an average 19% increase in California individual-policy health insurance rates, the second company to do so, after discovering miscalculations. online.wsj.com |
Spherix Announces Second Quarter 2010 Financial Results (PR Newswire) Spherix Incorporated , an innovator in biotechnology for therapy in diabetes and the metabolic syndrome, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported results for the three months ended June 30, 2010. us.rd.yahoo.com |
Alexza Pharma Still Has Room to Rise M.E. Garza submits: With an FDA decision due in early October, Alexza Pharmaceuticals' (ALXA) stock has been reacting very nicely in anticipation, making a string of higher highs and higher lows since early August.Last week, the Company issued a press release announcing that it will participate in two investor conferences, one at the Rodman & Renshaw Annual Global Investment Conference tomorrow, September 14, 2010 at 3:40 p.m. ET, and the other at the JMP Securities Healthcare Conference on Monday, September 27, 2010 at 2:00 p.m. ET.Complete Story » seekingalpha.com |
Trius to Participate in the Piper Jaffray Health Care Conference [GlobeNewswire] - SAN DIEGO -- Trius Therapeutics, Inc. announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will participate in an informal "fireside chat" with research analyst Edward Tenthoff at Piper Jaffray's 22nd Annual Health Care Conference. us.rd.yahoo.com |